Cargando…

Rasagiline effects on glucose metabolism, cognition, and tau in Alzheimer's dementia

BACKGROUND: A Phase II proof of concept (POC) randomized clinical trial was conducted to evaluate the effects of rasagiline, a monoamine oxidase B (MAO‐B) inhibitor approved for Parkinson disease, in mild to moderate Alzheimer's disease (AD). The primary objective was to determine if 1 mg of ra...

Descripción completa

Detalles Bibliográficos
Autores principales:	Matthews, Dawn C., Ritter, Aaron, Thomas, Ronald G., Andrews, Randolph D., Lukic, Ana S., Revta, Carolyn, Kinney, Jefferson W., Tousi, Babak, Leverenz, James B., Fillit, Howard, Zhong, Kate, Feldman, Howard H., Cummings, Jeffrey
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7882538/ https://www.ncbi.nlm.nih.gov/pubmed/33614888 http://dx.doi.org/10.1002/trc2.12106

Ejemplares similares

The Application of Zonisamide to Patients Suffering from Dementia with Lewy Bodies: Emerging Clinical Data
por: Tousi, Babak, et al.
Publicado: (2021)

5HT6 Antagonists in the Treatment of Alzheimer’s Dementia: Current Progress
por: Andrews, Megan, et al.
Publicado: (2018)

Rasagiline in treatment of Parkinson’s disease
por: Nayak, Lakshmi, et al.
Publicado: (2008)

Novel strategies for the prevention of dementia from Alzheimer's disease
por: Shineman, Diana W., et al.
Publicado: (2009)

The role of rasagiline in the treatment of Parkinson’s disease
por: Leegwater-Kim, Julie, et al.
Publicado: (2010)

Rasagiline Withdrawal Syndrome in Parkinson’s Disease
por: Solla, Paolo, et al.
Publicado: (2022)

Adjunctive therapy in Parkinson’s disease: the role of rasagiline
por: Gaines, Kathryn D, et al.
Publicado: (2012)

Linezolid and Rasagiline – A culprit for serotonin syndrome
por: Hisham, Mohamed, et al.
Publicado: (2016)

Value-Generating Exploratory Trials in Neurodegenerative Dementias
por: Friedman, Lauren G., et al.
Publicado: (2021)

Engineering of Reductive Aminases for Asymmetric Synthesis of Enantiopure Rasagiline
por: Zhang, Kai, et al.
Publicado: (2021)

Beyond amyloid: a diverse portfolio of novel drug discovery programs for Alzheimer's disease and related dementias
por: Lane, Rachel F, et al.
Publicado: (2011)

From a Parkinson's disease expert: Rasagiline and the Future of Therapy
por: Lakhan, Shaheen E
Publicado: (2007)

Role of rasagiline in treating Parkinson’s disease: Effect on disease progression
por: Malaty, Irene A, et al.
Publicado: (2009)

Striking Neurochemical and Behavioral Differences in the Mode of Action of Selegiline and Rasagiline
por: Harsing, Laszlo G., et al.
Publicado: (2023)

Rasagiline – a novel MAO B inhibitor in Parkinson’s disease therapy
por: Lecht, Shimon, et al.
Publicado: (2007)

Rasagiline and Rapid Symptomatic Motor Effect in Parkinson’s Disease: Review of Literature
por: Pistacchi, Michele, et al.
Publicado: (2013)

Treatment patterns and burden of behavioral disturbances in patients with dementia in the United States: a claims database analysis
por: Aigbogun, Myrlene Sanon, et al.
Publicado: (2019)

Rasagiline Ameliorates Olfactory Deficits in an Alpha-Synuclein Mouse Model of Parkinson's Disease
por: Petit, Géraldine H., et al.
Publicado: (2013)

Rasagiline for sleep disorders in patients with Parkinson’s disease: a prospective observational study
por: Schettino, Carla, et al.
Publicado: (2016)

Comparison of Selegiline and Rasagiline Therapies in Parkinson Disease: A Real-life Study
por: Peretz, Chava, et al.
Publicado: (2016)

Rasagiline, sleep quality and well-being in Parkinson’s disease: a pilot study
por: Mutti, Carlotta, et al.
Publicado: (2022)

Polymorphism of Drug Transporters, Rather Than Metabolizing Enzymes, Conditions the Pharmacokinetics of Rasagiline
por: Zubiaur, Pablo, et al.
Publicado: (2022)

Measurement of neurodegeneration using a multivariate early frame amyloid PET classifier
por: Matthews, Dawn C., et al.
Publicado: (2022)

The risk of melanoma with rasagiline compared with other antiparkinsonian medications: A retrospective cohort study in the United States medicare database
por: Johannes, Catherine B., et al.
Publicado: (2022)

Diverse therapeutic targets and biomarkers for Alzheimer's disease and related dementias: report on the Alzheimer's Drug Discovery Foundation 2012 International Conference on Alzheimer's Drug Discovery
por: Lane, Rachel F, et al.
Publicado: (2013)

The Contribution of Tau, Amyloid-Beta and Alpha-Synuclein Pathology to Dementia in Lewy Body Disorders
por: Irwin, David J., et al.
Publicado: (2018)

Definitions of dementia and predementia states in Alzheimer's disease and vascular cognitive impairment: consensus from the Canadian conference on diagnosis of dementia
por: Chertkow, Howard, et al.
Publicado: (2013)

Rasagiline protects against alpha-synuclein induced sensitivity to oxidative stress in dopaminergic cells
por: Chau, K.Y., et al.
Publicado: (2010)

The neuroprotective agent Rasagiline mesylate attenuates cardiac remodeling after experimental myocardial infarction
por: Varela, Aimilia, et al.
Publicado: (2017)

Rasagiline does not exacerbate autonomic blood pressure dysregulation in early or mild Parkinson’s disease
por: Oka, Hisayoshi, et al.
Publicado: (2021)

Rasagiline as Adjunct to Levodopa for Treatment of Parkinson's Disease: A Systematic Review and Meta-Analysis
por: Kano, Osamu, et al.
Publicado: (2022)

Curcumin modulation of L-dopa and rasagiline-induced neuroprotection in rotenone model of Parkinson’s disease
por: El-Shamarka, Marwa El-Sayed, et al.
Publicado: (2023)

The emerging role of bexarotene in the treatment of Alzheimer’s disease: current evidence
por: Tousi, Babak
Publicado: (2015)

I(1) Imidazoline Receptor: Novel Potential Cytoprotective Target of TVP1022, the S-Enantiomer of Rasagiline
por: Barac, Yaron D., et al.
Publicado: (2012)

Effect of the moist-heat sterilization on fabricated nanoscale solid lipid particles containing rasagiline mesylate
por: Viveksarathi, K., et al.
Publicado: (2015)

No synergism between bis(propyl)-cognitin and rasagiline on protecting dopaminergic neurons in Parkinson's disease mice
por: Zheng, Cheng-you, et al.
Publicado: (2016)

Reversed-Phase UHPLC Enantiomeric Separation of Rasagiline Salts Using a Chiralpak(®) AGP Column
por: Balaji, Nagarajan, et al.
Publicado: (2017)

Long-term safety and efficacy of adjunctive rasagiline in levodopa-treated Japanese patients with Parkinson’s disease
por: Hattori, Nobutaka, et al.
Publicado: (2019)

Neuroprotection with rasagiline in patients with macula-off retinal detachment: A randomized controlled pilot study
por: Yu, Siqing, et al.
Publicado: (2020)

Riluzole–Rasagiline Hybrids: Toward the Development of Multi-Target-Directed Ligands for Amyotrophic Lateral Sclerosis
por: Albertini, Claudia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fncpot0is5jnupfd96ka72m35u